GlassScriptPhysician profile
Toral A Patel
NPI 1902008006
$125,028.99
in general payments reported to CMS, 2019-2025
22 companies · $917 in 2025
The $917 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60K · 2020: $11K · 2021: $18K · 2022: $11K · 2023: $20K · 2024: $3,151 · 2025: $917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Consulting Fee: $5,800 · Food and Beverage: $4,100 · Travel and Lodging: $2,587 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,350.00 |
| Consulting Fee | $5,800.00 |
| Food and Beverage | $4,099.99 |
| Travel and Lodging | $2,586.99 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $51,689.38 | 2019-2023 | Cabenuva, Rukobia, Apretude |
| Melinta Therapeutics, LLC | $28,858.14 | 2019-2025 | Kimyrsa, Vabomere, Orbactiv |
| Gilead Sciences, INC. | $24,001.10 | 2019-2025 | Biktarvy |
| Merck Sharp & Dohme LLC | $13,285.18 | 2019-2025 | Delstrigo, Pifeltro, Zerbaxa |
| Theratechnologies INC. | $3,008.86 | 2019-2025 | Egrifta, Trogarzo |
| Glaxosmithkline, LLC. | $1,184.06 | 2019 | |
| Janssen Biotech, INC. | $669.23 | 2019-2023 | Symtuza |
| Paratek Pharmaceuticals, INC. | $392.16 | 2019-2025 | Nuzyra |
| Abbvie INC. | $387.81 | 2019-2025 | |
| Shionogi INC | $278.21 | 2019-2025 | Fetroja |
| Janssen Products, LP | $262.98 | 2019-2022 | |
| Napo Pharmaceuticals INC | $259.89 | 2019-2024 | Mytesi |
| Tetraphase Pharmaceuticals, INC. | $244.29 | 2019 | |
| Allergan, INC. | $121.34 | 2019-2020 | |
| Astellas Pharma US INC | $106.97 | 2019-2024 | Cresemba, Padcev |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nabriva Therapeutics, Plc | $64.99 | 2020-2021 | |
| Mayne Pharma Commercial LLC | $53.24 | 2019-2022 | |
| Insmed, INC. | $49.45 | 2025 | Arikayce |
| Cumberland Pharmaceuticals, INC. | $35.76 | 2019 | |
| Janssen Pharmaceuticals, INC | $30.64 | 2023 | Symtuza |
| Exact Sciences Corporation | $25.94 | 2025 | The Cologuard Plus Collection Kit |
| Ferring Pharmaceuticals INC. | $19.37 | 2023 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Toral Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.